Selective JAK1 Inhibition is a 21st Century science. At NS Pharma, we are investigating this therapeutic approach for the treatment of rare diseases like eosinophilic granulomatosis with polyangiitis (EGPA).
With JAK1 inhibition, we consider two important variables: potency and target selectivity. These aspects are crucial when developing safe and effective therapies. Higher potency means a lower dose of the drug is needed for it to have its intended effect. High selectivity helps to ensure that the drug interacts only with its intended target, minimizing the risk of side effects.
The main challenge of working with JAK1 inhibitors to treat EPGA is that different therapies are needed to treat distinct stages of EGPA – no single therapy has been found to treat all stages of this condition.1 Scientists are still working to understand the causes of EGPA fully. This is complex, as they believe several factors are involved.
On the plus side, if JAK1 inhibition is effective, researchers hope it could reduce symptoms of EGPA regardless of disease stage. This would present a treatment opportunity for many patients with EGPA, rather than just a select few. Researchers are currently conducting a Phase 2 clinical trial to evaluate its safety and effectiveness in treating EGPA.
EGPA is extremely rare, affecting just about 0.0017% of the population.2 This makes accessing diagnosis and effective treatment challenging for patients. If JAK1 inhibition for EGPA is successful, this therapy could support healthier and happier futures for people with EGPA.
1 Eosinophilic Granulomatosis with Polyangiitis – Vasculitis Foundation. Accessed on July 19, 2024.https://www.vasculitisfoundation.org/education/vasculitis-types/eosinophilic-granulomatosis-with-polyangiitis/
1 Eosinophilic Granulomatosis with Polyangiitis (EGPA) – American Lung Association. Accessed on July 19, 2024. https://www.lung.org/lung-health-diseases/lung-disease-lookup/egpa
2 Vaglio A, Buzio C, Zwerina J. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): state of the art. Allergy. 2013 Mar;68(3):261-73. doi: 10.1111/all.12088
